NCT07591649
- Conditions
- Acute Myelogenous Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
- Locations
-
- Mark Juckett, MD Minneapolis, Minnesota, United States
Clinical trial condition
Refractory AML
Explore clinical trials studying Refractory AML. Study availability and eligibility vary by location and protocol.
11 public trials
7 recruiting studies
Refractory AML trial results
NCT05735184
- Conditions
- AML With Mutated NPM1, Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, +19 more
- Locations
-
- Mayo Clinic - Phoenix Phoenix, Arizona, United States
- Moores UC San Diego Cancer Center La Jolla, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
- UCLA - Bowyer Oncology Center Los Angeles, California, United States
NCT06307054
- Conditions
- Hematologic Diseases, Hemic and Lymphatic Diseases, Leukemia, +6 more
- Locations
-
- Shanghai General Hospital Shanghai, Shanghai Municipality, China
NCT03850574
- Conditions
- Bone Marrow Diseases, Chronic Disease, Chronic Myelomonocytic Leukemia, +16 more
- Locations
-
- The Kirklin Clinic of UAB Hospital Birmingham, Alabama, United States
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- University of California Irvine Irvine, California, United States
- UCSD Moores Cancer Center La Jolla, California, United States
NCT06022003
- Conditions
- AML, Adult, FLT3-ITD, FLT3-TKD Mutation, +9 more
- Locations
-
- Amiens CHU Amiens, France
- Angers CHU Angers, France
- Hôpital d'Instruction des Armées PERCY Clamart, France
- CHU Estaing Clermont-Ferrand, France
Recruiting
Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML
NCT06737523
- Conditions
- Acute Myeloid Leukemia, Disease Attributes, Hematologic Diseases, +11 more
- Locations
-
- The First Affiliated Hospital of Xiamen University Xiamen, Fujian, China
Recruiting
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
NCT06316960
- Conditions
- AML, Childhood, C-KIT Mutation, Core Binding Factor Acute Myeloid Leukemia, +13 more
- Locations
-
- First Affiliated Hospital Of University of Science and Technology of China Hefei, Anhui, China
- The Second Hospital of Anhui Medical University Hefei, Anhui, China
- Guangzhou Women and Children Medical Center Guangzhou, Guangdong, China
- The First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi, China
Not Yet Recruiting
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
NCT07157514
- Conditions
- Acute Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, +15 more
- Locations
-
Not specified
NCT05193448
- Conditions
- FLT3-ITD, FLT3-TKD Mutation, Hematologic Diseases, +8 more
- Locations
-
- Amiens CHU Amiens, France
- Angers CHU Angers, France
- Avignon CH Avignon, France
- Bayonne CH Bayonne, France
Completed
Phase 1 Study of Quizartinib
NCT02675478
- Conditions
- Hematologic Diseases, Hemic and Lymphatic Diseases, Leukemia, +6 more
- Locations
-
- Tokyo, Japan